Corporate Presentation 2017

1

Awaken the body’s power™ to protect, restore & regenerate

What are post operative adhesions? Bands of scar tissue that form after most surgeries and stick to organs causing complications. Now, surgery’s single largest complication, cause of morbidities that lead to repeat surgeries, readmissions & longer length of stays. (Practical Guide to the prevention of Surgical Adhesions, CME/CE)

Painful Burden = Opportunity Hospitals’ burden, Surgeons’ nemesis, and patients’ nightmare

2

Risk of Adhesions v.

Infection, Hemorrhage

1:17 v.

1:500

Adhesion Awareness: A National Survey of Surgeons, World J. of Surgery, 2010

Executive Summary First-in-Class Drug Ready to capture $2.5B untapped market

3

•Clinical: Lead preparing for pivotal studies-first-in-class drug(Evitar™); •48 Patient double blind RCT placebo controlled study & FDA PIND completed •Final Study report available March 2017 for adhesion prevention •Secured Top KOL’s in the space to design and run pivotal program

•IP: Irrevocable exclusive world-wide license for Evitar™, patent expiry extended to 2038 with recent filing; provisional filed on 2nd indication; filing provisional on third indication in transplant in 2017—orphan and fast track possibilities •CMC: API cGMP in place, DMF’s filed in major markets, stability data available over 24 months; two clinical batches completed •Pipeline: Promising products positioned for reference leadership in other surgery adhesion prevention indications (spinal, ortho, etc.), and transplant (orphan and fast track possibilities ) •Commercial: adhesion prevention-significant growth potential- 90% of the 2.5 billion USD market is untapped

Evitar™ prevents adhesion formation & delivers clinically relevant outcomes Key to surgeon adoption, reimbursement & commands premium pricing

Milestones for 2017

4

Nov/’16 FDA PIND

POC Trial (N=48)

Completed Dec’16

Independent Medical

Review of Data

Completed Feb’17

QA Data Available Mar’17;

Engage in co-

development discussions

File Orphan Drug

Application EMA & FDA

Q2’17

Close Financing

$25M by end of Q3’17

Complete Dose

Ranging, GLP Tox & PK Studies

Q4’17-Q1’18

Near term inflection points creates value and mitigate risks

5

Hospital/Acute Care/Out-Patient Markets Reference leadership in product pipeline

DAMAGE OR INJURY HYPOXIA

Post Operative

Fibrosis

Transplant Delayed Graft

Function

Dermal Scar Revision

Abdomino- Pelvic Spine Ortho

Provisional patent

filing 2017

2017-Filing for ODD &

Breakthrough

Orphan & Fast Track

Provisional patent

filing 2017

General

“There is a significant unmet need in fibrosis, and this novel pharmaceutical

approach has potential,” stated Dr. James Greenberg, Chief of Gynecology at the

Faulkner Hospital and a Vice Chairman of Obstetrics & Gynecology at Brigham &

Women's Hospital, Harvard Medical School, Boston, MA. “I believe the approach and

efficacy shown sets a new standard of care in gynecology pelvic surgeries. For me it is

important that it is not a barrier or medical devices which are not that effective.”

EVITAR™ ADDRESSES MAJOR UNMET MEDICAL NEED First –in-Class Drug -Standard of Care for Surgeries

6

Post-operative complications Most sensitive surrogate marker for quality* ratings for hospitals

7

* *

*Annals of Surgery, 2011, 254 (6), 907-913

**JAMA Surg. 2016;151(6); Journal of Clinical Anaesthesia, Vo. 22, 2010; American J. of Cosmetic Surgery, Vol 22, 1, 2015

* **

**

Large Untapped Adhesion Prevention Market -Limited or no options for laparoscopic abdominal and pelvic procedures; the fastest growing surgical segment “First-in-Class Drug from Novel Biology could be ideal product” –Dr. Greenberg, Harvard Surgeon Adhesion related Adoption Drivers -Surgical complications slash profit margins from 5.8% to 0.1% (Jama Surgical May 11, 2016)

-30 day re-admission rates wither away hospital quality rating -Related medico-legal issues spike risk for hospitals and surgeons (Medico Legal Consequences, Int’l J. of Surgery, 2009)

-7 procedures accounted for 80% of surgeries, 80% of patient fatalities, 79% of complications and 80% of national inpatient costs (JAMA Surg. 2016;151(6))

Global Market ($2.5B)

Untapped Market

Current Penetration

Large Unmet Medical Need & Untapped Market Evitar™ First-in-Class Drug for Laparoscopic Use

8

0.0% 5.0%

With

Without

Hospital Profit Margin With or Without Complications

Profit Margin

ATTRACTIVE TARGET MARKETS Underserved and limited or no options with room for growth

Market Potential 9 + million procedures in US 30+ million globally Market Needs Limited or no viable solutions laparoscopic procedures An easy to use, effective and broad coverage would meet the need, accelerate adoption and realize the potential

Adhesions from Abdominal &

Pelvic Surgeries

Market Potential 54 million Americans over 65 Spine industry grown from $300M (1997) to $13B (2012) 1.5+ million procedures in US 3+ million procedures globally Market Needs CMS MS-DRG codes increased reimbursement by 20% Fibrosis may account for 20-36% of FBSS* & makes reoperations more difficult Reducing fibrosis with a safe and effective product would meet the need

Epidural Fibrosis following Spinal

Surgery Market Potential 6+ million digestive system 1+ million respiratory system 7+ million CV 700K knee replacements 1.2+ million urinary system Market Needs Fibrosis complications lead to hospitalizations, re-operations and medico-legal issues Customized product design with input from surgical team could dominate the space

Other surgical procedures (US data)

9

No Current Standard of Care Creates unmet medical need

Seprafilm® or Interceed®

Barriers Method

Adept®

Barrier Method using an

instillation

Significant Limitations •Not FDA Approved for laparoscopic surgeries •Seprafilm®: Hard to use & handle-sticky; leaks with anastomosis •Near perfect hemostasis environment required for Interceed® •Adhesions still form

Significant Limitations •Infection & swelling reported in trial •Approved : gynecological laparoscopic adhesiolysis, clean cases •Efficacy is marginal (9.8%) difference from Lactated Ringers solution (FDA Panel Review) •Contraindicated to general surgery •Adhesions still form

A clear need for a product that is easy to use in all procedures, applies quickly and achieves broad coverage that prevents adhesions throughout

Seprafilm , Interceed and Adept are registered trademarks for Sanofi, Johnson & Johnson and Baxter respectively

1975 Today

Anti-inflammatory & Steroids Aspirin to methylpredinisolone

1990 Barrier Devices

2009

Adhesion Literature Suggests: Re-alignment of Cellular Metabolism

•Restoring balance at cellular level may be possible within hours of surgery*

•Rapidly restoring tissue homeostasis enhances normal resolution*

•Shifts the gene signalling pathways activated by prolonged hypoxia and oxidative stress away from adhesion formation*

* Awoniyi O. Awonuga, J. B. Diamond, Michael, et al. (2014). Advances in the Pathogenesis of Adhesion Development: The Role of Oxidative Stress. Reproductive Sciences, 1-14.

EvitarTM Moves Beyond “Barrier” Thinking First-in-Class Patented Drug could be the ideal product

11

T i s s u e M a r k e r s o f A d h e s i o n s Omental Milky Spots appear and increase with adhesion formation

Milky spots are corpuscles found in the omental glumeruli measuring 0.1-2 mm in size, hardly visible to the naked eye, and under low magnification look like tufts of cotton wool. They were first observed as dense corpuscles resembling cotton wool in the omentum and pleura of rabbits in 1863 by Recklinghausen. In 1874, Ranvier confirmed this discovery and named these corpuscles milky spots. Milky spots are characterized by a permanent glomus pattern of vascular structure, specific cellular population and a specialized mesothelial lining. In humans, milky spots comprise of macrophages (70%), B-lymphocytes (10%), T-lymphocytes (10%), mast cells, and stromal cells. The activation of milky spot growth in size and number occurs within 6 hours of abdominal surgery. It plays a key role in adhesion formation, at least in part by release of fibrotic mediators such as HIF1a, TGF-ẞ1, TGFB2, VEGF.

Wingerden, J., et. al, Poststernotomy mediastinitis: a classification to initiate and evaluate reconstructive management based on evidence from a structured review. Journal of Cardiothoracic Surgery 9(1):179 Cranshaw, M. L. and L. V. Leak, Milky spots of the omentum: a source of peritoneal cells in the normal and stimulated animal. Arch Histol Cytol, 1990. 53 Suppl: p. 165-77 Shimotsuma, M., et al., Milky spots in the human greater omentum. Macroscopic and histological identification. Acta Anat (Basel), 1989. 136 (3): p. 211-6. Shimotsuma, M., et al., Cellular subsets of the milky spots in the human greater omentum. Cell Tissue Res, 1991. 264 (3): p. 599-601. Gomez-Gil et. al., Involvement of TGF-B 3 and betaglycan in the cytoarchitecture of omental adhesions, Journal of Surgical Research, 2014, 187, p. 699-711.

Immunostaining of native and activated omentum for stromal- cell-derived factor-1 α (SDF-1 α ). a Native omentum showing concentrated SDF-1 α immunoreactivity in milky spots ( arrow ) and patchy staining in areas around blood vessels. b Activated omentum showing

13

Evitar™

Novel Approach-Cellular Modulation

a. Milky Spots dubbed for its milky appearance by anatomist Ranvier contain inflammatory and immune cells and are known to secrete TFG-B, well studied fibrotic mediator (Gomez-Gil et al. 2014; Hall, Heel & Platell, 1998; Vanvugt et al. 1996; Shimotsuma et al. 1993; Shimotsuma, Kawate et al. 1989; Wijffels. Beelen et al. 1992; Platell, Cooper et al. 2000; Shimotsuma M,1989; Shimotsuma, Simpson-Morgan et al., 1994;

Evitar™ Controls Milky Spot Secretions of Cytokines Restore the balance in favor of normal resolution vs. adhesion formation

Peritoneal Injury

Milky Spots a

Normally cover 1-2% of omentum surface area remains constant

TGF-ẞ3 , tPA, ↑ fibrinolysis

Anti-fibrotic

TGF-ẞ1, TGF-ẞ2 VEGF, PAI

fibrin deposition

Pro-fibrotic

Normal Healing (Peritoneal Repair)

TGF-ẞ3 tPA fibrinolysis Anti-fibrotic

TGF-ẞ1, TGF-ẞ1 VEGF, PAI

Pro-fibrotic, ↑ fibrin

deposition

Milky Spots a

Expand to cover 40-60% of omentum surface area

Adhesion or Fibrosis Formation

Normal Resolution Fibrosis Formation Evitar™

Differentiation Parameters

Evitar™

GYNECARE INTERCEED® (Johnson & Johnson)

ADEPT ® (Baxter)

(Sanofi-

Genzyme)

Laparoscopic use Yes administered laparoscopically in

current trial

Not FDA Approved Yes

FDA Approved with conditions

Not FDA Approved

Fined by US DOJ for use

Type Drug

Sterile Aqueous form

Device

Synthetic fabric

Device

Liquid instillation

Device

Bioresorable Film

Ease of use Easily applied in <1 min through

commonly found syringes

Education & training required

Known to extend procedure time

Easy

Significant volume 1000ml in periitoneal

cavity

Education & training required

Known to extend procedure time

Safety Issues No AE’s reported in current trial

AE’s reported AE’s reported AE’s reported

Currently under a Petition to FDA to

remove off market

EVITAR™ First-in-Class Drug Easy to use, quick to apply & laparoscopic friendly

15

“DROP IT IN EVERY PROCEDURE”

16

Value Propositions Balances customer needs & maintains strong margins

Surgeon

<1 min. application time, no change in habits or training

Easily works equally well in open or

scope procedures

Reduces operation time, potential complications

Hospital

Priced right as a % of total procedure, no capital investment required

One product for many procedures, economies of scale

Saves OR time , reduces

complications and readmissions

Margins 90%+

Drug

Indication

Preclinical Phase

I

Phase

II

N=48

patients

Phase

III

N=300+

patients

Regulatory

505(b)1 Pathway Potential

Orphan and Breakthrough

Possibility with Expedited

Evitar™

100% enrolled

•Current trial is a double blind placebo controlled randomized study with both a laparoscopic arm (N=38) and laparotomy (N=10), both randomized 1 to 1 in myomectomies (removal of fibroids) with 6-8 week post-op laparoscopy second look follow-up which is the gold standard for assessing adhesions

•Blinded Independent Reviewers (in Progress): •Togas Tulandi MD, MHCM, Professor & Interim Chair of Obstetrics and Gynecology, and Milton Leong Chair in Reproductive Medicine, McGill University, Interim Chief of Department of Obstetrics and Gynecology, McGill University Health Center •Antonio Rosario Garguilio, MD, Assistant Professor, Harvard Medical School, Infertility and Reproductive Surgery Obstetrics/Gynecology •Dr. Donna Chizen, MD, Reproductive Endocrinologist, Obstetrics and Gynecology, University of Saskatchewan

ACCELERATED CLINICAL PATHWAY Elective surgeries, clear endpoints & small trials

17

File ODD Application in US & EU

CLINICAL TRIAL SUMMARY

18

Proposed Indication As an adjunct to good to surgical technique, Evitar reduces adhesion formation following abdominal pelvic surgeries.

Study Design Double blind, placebo controlled randomized trial

Sample size N= 48, with 24 subjects receiving the treatment (Evitar™) ; 24 subjects receiving the placebo laparoscopically; with 10 subjects undergoing a myomectomy by laparotomy.

Primary Endpoint Statistically significant reduction in adhesions observed in the Evitar™ treated group compared to placebo at 6-8 weeks post-myomectomy. Based on the analysis approach the primary endpoint will be met if the Treatment group has a statistically significant fewer patients in the “Adhesions” category (and therefore, 30% more in the “Non-Adhesions” category) compared to the Placebo group.

Secondary Endpoint Establish safety and tolerability of formulation and fixed dosage of Evitar into the peritoneal cavity

Efficacy The ability of Evitar™ to reduce post surgical adhesions will be determined during the 8-week post-operation follow up laparoscopic examination. Both the incidence and the severity of adhesions will be assessed. The incidence of adhesions will be determined visually. Digital recording of all surgeries and sites where the uterine surface was opened/incised/cauterized/sutured will be compared between first and second surgeries. Severity of the adhesions will be assessed using the AFS (American Fertility Society) scoring system, which evaluates the extent and aspect of adhesions at four anatomical sites, right ovary, right tube, left ovary, left tube. All findings will be recorded in the subject’s case report form (CRF).

CLINICAL TRIAL SUMMARY

19

Inclusion criteria Subjects are female Subjects are 18 years of age or older at the time of consent Subjects have a BMI between 17-40 Subjects must have signed informed consent form Subjects have a preoperative diagnosis of uterine fibroids and plan to have a myomectomy completed surgically as part of their standard care Subjects must have a physical examination and compliance assessment Main exclusion criteria are: Subjects whose BMI is outside the range of 17-40 Subjects participating in another clinical trial with a drug or device Subjects who have participated in a clinical trial with a drug or device within 30 days prior to this study Subjects with suspected or diagnosed pregnancy Subjects with undiagnosed vaginal bleeding Subjects with suspected intraabdominal infection Subjects who are immunocompromised Subjects diagnosed with cancer Subjects treated with hemostatic agents (e.g. fibrin sealant, collagen, oxidized cellulose) Subjects treated with adhesion prevention agents other than the Anti-Adhesion product (APP) (e.g. Intergrel Adhesion Prevention Solution, Seprafilm Membrane) Subjects taking anti-epileptic medications Subjects who have been treated with Methotrexate or other chemotherapeutics agents Subjects with an American Fertility Society score of Stage D at the time of myomectomy as determined by the surgeon

20

Pivotal Clinical Strategy with Orphan Designation

mPOC –in vitro-markers -tracer study on glutamine to uncover metabolism

Safety -GLP Tox -Dose Response

Evitar Phase 2B/3 Registration Trial

First Approval in Orphan Indication

2021

Regulatory Interactions

cPOC

cPOC

Additional Registration Trials mPOC = mechanistic proof of concept

cPOC = clinical proof of concept

21

Evitar™ Pivotal Clinical Program Synopsis Proposed Indication First in class drug to improve fertility in patients undergoing

myomectomies, laparoscopic or laparotomic) by reducing and/or preventing adhesion formation

Primary Endpoint Improvement in fertility rate of 50% from baseline (literature suggests that anywhere from 33% to 50% of women undergoing myomectomies without any adhesion prevention products do conceive). Confirmed pregnancy by ultrasound fetal heart rate at 6 weeks

Secondary Endpoint Presence of adhesions in abdominal wall by imaging at 6 to 8 weeks

Inclusion criteria Females, age18-37, male partner is ok, tubes are ok, unexplained infertility (trying for one year without success), presence of one myoma <3cm in the uterus determined by transvaginal ultrasound

Follow up Period One year from last patient in; 24 months to 36 months

Proposed Sample Size 300

Proposed Trial Centers 7 (4 in Europe; 2 US & 1 in Canada) primary centers Other centers in Latin America, CES, Japan, AU, S. Korea and India possible

22

PROVEN TEAM Relevant experience-clinical, regulatory, legal, finance, marketing & sales

Len Smith, MSc., JD Strategic Counsel

Sanj Singh, MBA CEO

Lynne Robertson, MS, PhD

Chief Operating Officer

Over 20 years of industry experience in leadership positions; building top teams & strong strategic relationships, business development and raising capital. Board of Directors, BioteCanada. Formerly of: Co-founder, President & CEO of AdeTherapeutics Inc.

Over 29 years of experience in biomedical and pharmaceutical industries. Concept through commercial launch, including discovery, CMC and clinical development, regulatory and compliance, program management and executive leadership. Experience with medical devices, combos, Rx and OTC drugs in Europe and North America. Formerly of Quintiles, KOS, Schering Plough, Mylan, Wyeth Ayerst and cofounder of Gwen Ryan Solutions pharma consulting.

Over 20 years crafting and carrying out strategies for transactions and operations relating to innovative technologies and products leading to growth and profits Structuring and negotiating technology, financing, and corporate deals (licenses, acquisitions, collaborations, joint ventures, mergers, etc.) and other contracts; board, regulatory compliance, IP strategy. Formerly of Valeant, Medicis & Novo Nordisk

Zahir Lavji, Chairman Previous President of Abbott Japan EVP of Int’l Marketing, Abbott

Bill Densel, CEO CheckCap Previous CEO-Beacon Medical Director Marketing & Sales, Biosurgery, Genzyme

Steven Damon CEO 4P Therapeutics Previous VP of Altea, Durect, Kimberly Clark

Board of Directors

James Hattersely Sr. VP BD, Adherium Previous Nektar, Sun Pharma, Antares, & Abbott

Jason Ding, CPA, CBV Previous Sr. Life science practice leader, Deloitte

Saad Gilani Financier, Sr. Portfolio Advisor, Yorkville Advisors

Guy-Jean Savoir Director Carnot Laboratories Founder, Investor, Diversified Corporate Holdings

Drug

Indication

POC

In Vitro

POC Animal Clinical

Trials

NDA Filing

Market

Launch

IP Expiry

TTX-330-Spinal

TTX-332-Transplant*

Pipeline in Acute Care/Hospital Prepping for IND in 2018

23

Animal data & IP data available along with Clinical & Regulatory development for both *TTX-332 will be rolled into a Newco with a 24 month IND development program

ENGINEERED VALUE Timeline, data & pipeline drive value creation

PIND FDA meeting &

Complete Phase I/II Trial

Data Lock Jan 2017

Double blind data read out

File Orphan Designation

Prep for pivotal trial in lead indication in

Western EU& USA Begin Co

Development License

Discussions

Major market license through co-development in Q4-2017-Q1-

2018

Market entry for

lead expected 2021

Q1-’17

Q2-3-’17

24

Corporate Presentation For more information

Sanj Singh, CEO Email: sanj@templerx.com

Mobile: +1306 261 5189

Lynne Robertson, COO Email:

lynne@templerx.com Mobile: +1 401 744 2718

25

Awaken the body’s power™ to protect, restore & regenerate

Market & Product Insight from our scientific, medical advisory board of surgeons

& payer

Mitigate Risk through validation

Quality differentiated products for major

unmet medical need

•Unmet medical need, clinical trial, reimbursement &product design vetted by SAB prior to acquiring IP and initiating development

•Breakthrough designation, orphan and/or 505(b)2 provides for rapid clinical development

•Disease modifying based on clinicians’ & payers’ input

•Value proposition: Reduce repeat procedures, lower re-admissions rates & length of stays

•Reducing complications increases hospital quality rating & improves operating margins

26

Market Driven Product Development Approach We go for standard of care where none exists

References

27

Amit Soneja, Magdalena Drews, Tadeusz Malinski. "Role of Nitric Oxide, nitroxidative and oxidative stress in wound healing." Pharmacological Reports 57 (2005): 108-119. Awoniyi O. Awonuga, Jimmy Belotte, Suleiman Abuanzeh, Nicole M. Fletcher, Michael P. Diamond and Ghassan M. Saed. "Advances in the Pathogenesis of Adhesion Development: The Role of Oxidative Stress." Reproductive Sciences (2014): 1-14. Burger, Daniel B Hinshaw and Jeanne M. "Protective Effect of Glutamine on Endothelial Cell ATP in Oxidant Injury." Journal of Surgical Research 49 (1990): 222-227. Chan, Susan Yung and Tak Mao. "Intrinsic Cells: Mesothelial Cells-Central Players in Regulating Inflammation and Resolution." Peritoneal Dialysis International 29 (2008): S21-S27. Diamond, Ghassan M. Saed and Michael P. "Apoptosis and proliferation of human peritoneal fibroblasts in response to hypoxia." Fertility and Sterility 78.1 (2002): 137-143. Duron, Jean-Jacques. "Postoperative intraperitoneal adhesion pathophysiology." The Association of Coloproctology of Great Britain and Ireland 9 (2007): 14-24. Fieren, Marien Willem Johan Adriaan. "The Local Inflammatory Responses to Infection of the Peritoneal Cavity in Humans: Their Regulation by Cytokines, Macrophages and Other Leukocytes." Mediators of Inflammation (2012): 1-9. Jing Fan, Jurre J Kamphorst1, Robin Mathew, Michelle K Chung, Eileen White, Tomer Shlomi,and Joshua D Rabinowitz. "Glutamine-driven oxidative phosphorylation is a majorATP source in transformed mammalian cells in both normoxia and hypoxia." Molecular Systems Biology 9.712 (2013): 1-11. Kar Neng Lai, Sydney C.W. Tang, and Joseph C.K. Leung. "Infllammation and Fibrosis: Mediators of Inflammation and Fibrosis." Peritoneal Dialysis International 27 (2006): S65-S71. Kayo Kaneko, Chieko Hamada, and Yasuhiko Tomino. "Peritoneal Fibrosis Intervention." Peritoneal Dialysis International 27 (2006): S82-S86. Klaus Kratochwill, Michael Boehm, Rebecca Herzog, Anton Michael Lichtenauer, Elisabeth Salzer, Michael Lechner, Lilian Kuster, Konstantin Bergmeister, Andreas Rizzi, Bernd Mayer and Christoph Aufricht. "Alanyl-glutamine dipeptide restores the cytoprotective stress proteome of mesothelial cells exposed to peritoneal dialysis fluids." Nephrology Dialysis Transplant 27 (2012): 937-946. Kuan-Yu Hung, Kuan-Dun Wu, and Tun-Jun Tsai. "In vitro study of peritoneal fibrosis." Peritoneal Dialysis International 27 (2007): S72-S75. M.M. Binda, C.R. Molinas, and P.R. Koninckx. "Reactive Oxygen species and adhesion formation: clinical implications in adhesion prevention." Human Reproduction 18.12 (2003): 2503-2507. Masataka Shimotsuma, Toshio Takahashi, Mitsuhiro Kawata, and Kazimierz Dux. "Cellular subsets of the milky spots in the human greater omentum." Cell Tissue and Research 264 (1991): 599-601. Natalia O. Litbarg, Krishnamurthy P. Gudehithlu, Perianna Sethupathi, Jose A. L. Arruda, George Dunea, Ashok K. Singh. "Activated omentum becomes rich in factors that promote healing and tissue regeneration." Cell Tissue and Research 328 (2007): 487–497. Newsholme, Philip. "Why is L-Glutamine Metabolism Important to Cells of the Immune System in Health, Postinjury, Surgery or Infection." The Journal of Nutrition-American Society of Nutritional Sciences (2001): 2515s-2522s. R. Curi, C.J. Lagranha, S.Q. Doi, D.F. Sellitti, J. Procopio, T.C. Pithon-Curi, M. Corless, and P. Newsholme. "Molecular Mechanisms of Glutamine Action." Journal of Cellular Physiology 204 (2005): 392-401. Saed GM, Collins KL, Diamond MP. "Transforming Growth Factors b1, b2 and b3 and their Receptors are Differentially Expressed in Human Peritoneal Fibroblasts in Response to Hypoxia." American Journal of Reproductive Immunology 48 (2002): 387-393. Shivanee Shah, Erin Lowery, Rudolf K. Braun, Alicia Martin, Nick Huang, Melissa Medina, Periannan Sethupathi, Yoichi Seki, Mariko Takami, Kathryn Byrne, Christopher Wigfield, Robert B. Love, Makio Iwashima. "Cellular Basis of Tissue Regeneration by Omentum." PloS One 7.6 (2012): 2012. Steven E. Mutsaers, Jill E. Bishop, Gus McGrouther, Geoffrey J. Laurent. "Mechanisms of Tissue Repair: from Wound Healing to Fibrosis." International Journal of Biochemistry and Cell Biology 29.1 (1997): 5-17. STEVEN E. MUTSAERS, JILL E. BISHOP, GUS McGROUTHER, GEOFFREY J. LAURENT. "Mechanisms of Tissue Repair: from Wound Healing to Fibrosis." International Journal of Biochemistry and Cell Biology 29.1 (1997): 5-17. Toshio Sakiyama, Mark W. Musch, Mark J. Ropeleski, Hirohito Tsubouchi and Eugene B. Chang. "Glutamine Increases Autophagy Under Basal and Stressed Conditions in Intestinal Epithelial Cells." Gastroenterology 136 (2009): 924-932. Trew, Geoffrey. "Consensus in adhesion reduction management-Supplement." The Obstetrician and Gynecologist 6.2 (2004). Valerie I. Shavell, Ghassan M. Saed, and Michael Diamond. "Cellular Metabolism:Contribution to Postoperative Adhesion Development." Reproductive Sciences 16 (2009): 627-634. Vero´nica Go´mez-Gil, Gemma Pascual, Ba´rbara Pe´rez-Ko¨hler, Alberto Cifuentes, Julia Buja´n, and Juan M. Bello´n. "Involvement of transforming growth factor-b3 and betaglycan in the cytoarchitecture of postoperative omental adhesions." Journal of Surgical Research 187 (2014): 699-711. Yoshimi Sekiguchi, Jung Zhang, Sarah Patterson, Limin Liu, Chieko Hamada, Yashuhiko Tomino, Peter J. Margetts. "Rapamychin inhibits transforming growth factor beta-induced peritoneal angiogenesis by blocking secondary hypoxic response." Journal of Cell Molecular Medicine 16.8 (2012): 1934-1945.